Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
|
Trubion Pharmaceuticals, Inc.http://www.trubion.com Trubion Pharmaceuticals, Seattle WA, United States of America. Trubion Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat inflammatory disease and cancer. The company utilizes Ticker - Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial ResultsThursday 5th of November 2009 16:00-- In Sept. 2009, patient enrollment was completed in the second Phase 2b study (2203) of TRU-015 for RA.2009 Financial Guidance The company has revised its 2009 guidance after taking into account its collaboration agreement with Facet. As a result, the company has lowered its anticipated annual burn rate from $30 million-$35 million to $0-$5 million. No changes have been made to anticipated revenues for 2009. The revised guidance is as follows:
-- Reiterate 2009 revenues of approximately $15 million to $20 million; and
-- Revised 2009 operating cash requirements are now expected to be
approximately $0 to $5 million.
This guidance does not include any additional cash receipts associated with potential new partnerships. Conference Call Details Trubion will host a conference call and webcast to discuss its third quarter and nine months ended Sept. 30, 2009, financial results and provide an update on business activities. The call will be held Nov. 5 at 2 p.m. Pacific Time, 5 p.m. Eastern Time. The live event will be available from Trubion's website at http://investors.trubion.com, or by calling (703) 639-1156 or (866) 238-0637. A replay of the discussion will be available beginning at 8 p.m. Eastern Time from Trubion's website or by calling (703) 925-2533 or (888) 266-2081 and entering 1408250. The telephone replay will be available until midnight, Nov. 11, 2009. About Trubion Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm. Forward-Looking Statements Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the potential development and commercialization of TRU-015. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the Company's collaborations, including the risk that the Company and Pfizer with regard to TRU-015 and SBI-087, and the Company and Facet with regard to TRU-016, are unable to advance their respective clinical development programs and regulatory applications and action at the expected rate, the risk that the Company is unable to develop or commercialize its clinical-stage products, the risk that the Company does not achieve the financial results that it expects during 2010 and such other risks as are identified in the Company's quarterly report on Form 10-Q for the period ended Sept. 30, 2009, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.
Contact:
Jim DeNike
Senior Director, Corporate Communications
Trubion Pharmaceuticals, Inc.
(206) 838-0500
jdenike@trubion.com
http://www.trubion.com
Waggener Edstrom Worldwide Healthcare
Amy Petty
Senior Account Executive
(617) 576-5788
amyp@waggeneredstrom.com
TRBN-G
(Tables Follow)
TRUBION PHARMACEUTICALS. INC.
STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
Three months ended Nine months ended
September 30, September 30,
----------------- -----------------
2009 2008 2009 2008
---- ---- ---- ----
Revenue $4,452 $3,766 $12,783 $12,197
Operating expenses:
Research and
development 7,410 7,397 27,587 23,302
General and
administrative 3,146 2,987 8,877 8,985
----- ----- ----- -----
Total operating
expenses 10,556 10,384 36,464 32,287
------ ------ ------ ------
Loss from
operations (6,104) (6,618) (23,681) (20,090)
Interest income 8 370 162 1,585
Interest expense (131) (334) (409) (677)
---- ---- ---- ----
Net loss $(6,227) $(6,582) $(23,928) $(19,182)
======= ======= ======== ========
Basic and diluted
net loss per share $(0.33) $(0.37) $(1.31) $(1.07)
====== ====== ====== ======
Shares used in
computation of basic
and diluted net loss
per share 18,868 17,859 18,267 17,847
====== ====== ====== ======
September 30 December 31,
2009 2008
---- ----
Balance Sheet Data:
Cash and cash
equivalents $31,811 $29,969
Investments 29,920 22,928
Total assets 72,676 67,290
Deferred revenue 37,054 19,493
Total stockholders'
equity 19,017 31,468
SOURCE Trubion Pharmaceuticals, Inc. Browse other news from this organisation: Trubion Pharmaceuticals, Inc. Source PR Newswire  |
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
